Marcie Riches MD MS

Oncology•Chapel Hill, NC

Hematologic Oncology

Professor, University of North Carolina Director, BMT Program

Join to View Full Profile

101 Manning DrChapel Hill, NC 27514
Phone+1 919-966-3048
Fax+1 919-966-6735

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2000 - 2003
University of Kentucky College of MedicineResidency, Internal Medicine, 1996 - 1999
University of Kentucky College of MedicineClass of 1997

Certifications & Licensure

NC State Medical License 2015 - 2025
FL State Medical License 2009 - 2017
MN State Medical License 2004 - 2010
IL State Medical License 2000 - 2005
KY State Medical License 1998 - 2001
American Board of Internal Medicine Hematology

Clinical Trials

CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant Start of enrollment: 2003 Sep 01
Terminated
Phase 1
Zevalin-beam for Aggressive Lymphoma Start of enrollment: 2007 Jun 01
Completed
Phase 3
Phase II Trial of Pentostatin and Targeted Busulfan Start of enrollment: 2007 Jul 01
Completed
Phase 2
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) Start of enrollment: 2009 Apr 01
Completed
Phase 2
Stem Cell Related Donor Safety Study Start of enrollment: 2010 Jan 01
Completed
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma Start of enrollment: 2009 Jun 18
Completed
Phase 2
Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD) Start of enrollment: 2010 Apr 01
Completed
Phase 1, Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RECRUITING
The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies. Start of enrollment: 2012 Jul 01
Terminated
Phase 2
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease Start of enrollment: 2012 Nov 14
Completed
Phase 1, Phase 2
Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease Start of enrollment: 2014 Oct 29
Completed
Phase 1
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies Start of enrollment: 2013 Aug 01
Completed
Phase 3
In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis Start of enrollment: 2014 Mar 25
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

7 citations
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.
Joshua A Hill, Michael J Martens, Jo-Anne H Young, Kavita Bhavsar, Jianqun Kou
Clinical Infectious Diseases. 2024-08-16
6 citations
Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30lymphoma: a phase 1 study.
Natalie S Grover, George Hucks, Marcie L Riches, Anastasia Ivanova, Dominic T Moore
The Lancet. Haematology. 2024-05-01
1 citations
Defining and Grading Infections in Clinical Trials Involving Hematopoietic Cell Transplantation: A Report From the BMT CTN Infectious Disease Technical Committee.
Zainab Shahid, Aaron M Etra, John E Levine, Marcie L Riches, Aliyah Baluch
Transplantation and Cellular Therapy. 2024-05-01

Journal Articles

Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms and Less Complete Recovery at 1-Year Compared to Unrelated Donors
Parameswaran N Hari, David A Jacobsohn, Joseph P McGuirk, Mary M Horowitz, Walter Longo, Thomas Spitzer, Daniel J Weisdorf, Shahram Mori, David C Delgado, Marcie L Ric..., Haematologica

Press Mentions

COVID-19 Prevention Is Essential for Bone Marrow Transplant PatientsFebruary 9th, 2021

Marcie Riches MD MS

Dr. Riches is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.